HCAT - NASDAQ
Health Catalyst, Inc.
$1.33
+1.9%Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
At a Glance
Live SnapshotHealth Catalyst, Inc. Management Team
Mr. Kevin Freeman
Chief Commercial Officer
Compensation
$598,658
Mr. Daniel D. Burton
Chief Executive Officer & Director
Compensation
$808,823
Mr. Jason Alger
Chief Financial Officer
Compensation
$460,574
Mr. Daniel LeSueur
Chief Operating Officer
Ms. Linda Llewelyn
Chief People Officer
Compensation
$485,113
Mr. Kyle J. Salyers
Chief Strategy Officer & Senior Vice President of Corporate Development
Mr. Dave Ross
Chief Technology Officer
Mr. Benjamin Landry
General Counsel & Secretary of the Board
Compensation
$505,226
Mr. Jeffrey P. Selander
Senior Vice President of International
Ms. Amanda Flanders
Senior Vice President of Marketing & Communications
Health Catalyst, Inc. Insider Positioning
During the last 12 months, insiders have sold $341K worth of HCAT shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
75.4K
200.68K
-201K
-$201K
9-12 Months
0
0.00
40.8K
140.57K
-141K
-$141K
Top Buyers
No buying activity
Top Sellers
Larson-Green Julie
Director
$128K
Landry Benjamin
Officer: General Counsel
$127K
Burton Daniel D.
Director, Officer: Chief Executive Officer
$28K
Freeman Kevin Lee
Officer: Chief Commercial Officer
$15K
Lesueur Daniel
Officer: Chief Operating Officer
$12K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $341K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
HCAT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2024 N/A | May 19, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 29, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 12, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.